Zheng Quan Ri Bao Wang·2025-12-07 10:24Core Insights - The 2025 National Medical Insurance Drug List was officially announced on December 7, 2023, in Guangzhou, including the addition of the BTK inhibitor, Ibrutinib (brand name: Acalbrutinib), developed by Nocera Pharmaceuticals, for the first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients [1][2] - Acalbrutinib has also successfully renewed its indications for previously treated CLL/SLL, Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL) [1] - The new drug list will be implemented starting January 1, 2026, and was released during the 2025 Innovative Drug High-Quality Development Conference [1] Company Highlights - Nocera Pharmaceuticals showcased its core pipeline and innovative highlights at the conference, representing innovative drug companies [1] - Acalbrutinib, as a result of the national "Major New Drug Creation" initiative, demonstrates nearly 100% target selectivity for BTK, with minimal inter-individual variability and no significant inhibition of other kinases, ensuring efficacy while avoiding adverse effects due to off-target effects [2] - The drug offers the convenience of once-daily oral administration, facilitating continuous treatment for patients [2]